Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Director William R. Ringo sold 31,000 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $14.37, for a total transaction of $445,470.00. Following the completion of the transaction, the director now directly owns 31,800 shares in the company, valued at $456,966. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) traded down 3.85% during midday trading on Friday, hitting $13.75. 1,664,928 shares of the company traded hands. The stock has a 50 day moving average of $11.44 and a 200-day moving average of $7.79. Sangamo Therapeutics, Inc. has a 52 week low of $2.65 and a 52 week high of $15.05. The stock’s market capitalization is $1.15 billion.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $8.30 million for the quarter, compared to the consensus estimate of $5.82 million. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. Sangamo Therapeutics’s quarterly revenue was up 124.3% on a year-over-year basis. During the same period last year, the firm posted ($0.38) earnings per share. Equities analysts forecast that Sangamo Therapeutics, Inc. will post ($0.82) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/22/william-r-ringo-sells-31000-shares-of-sangamo-therapeutics-inc-sgmo-stock.html.

SGMO has been the topic of several recent analyst reports. Wells Fargo & Company reissued an “outperform” rating and issued a $30.00 target price (up from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. Jefferies Group LLC reaffirmed a “buy” rating and set a $18.00 price target on shares of Sangamo Therapeutics in a report on Thursday, September 14th. Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Finally, BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $14.40.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. HighTower Advisors LLC raised its stake in Sangamo Therapeutics by 0.3% in the first quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 100 shares in the last quarter. Blair William & Co. IL raised its stake in Sangamo Therapeutics by 4.3% in the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 500 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Sangamo Therapeutics by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock valued at $670,000 after purchasing an additional 513 shares in the last quarter. Principal Financial Group Inc. raised its stake in Sangamo Therapeutics by 6.8% in the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 832 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in Sangamo Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock valued at $2,353,000 after purchasing an additional 1,558 shares in the last quarter. 63.43% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.